ClinicalTrials.gg
RecruitingNCT07188584Updated Dec 9, 2025

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

A Phase 3 interventional study of Reduced-Target Radiotherapy and Conventional Full-Target Radiotherapy in Nasopharyngeal Carcinoma (NPC), sponsored by Ming-Yuan Chen. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Ming-Yuan Chen · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen — 10 open to participants now, 10 under way, 3 of them phase 3. Nasopharyngeal Carcinoma · Ming-Yuan Chen.

Started
2025
with 5 others
Phase 3
3 of 10
3 open now
Registered
7th of 10
by date

Among the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen, this one is one of 6 that started in 2025, is one of 3 in phase 3, and was the 7th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

10 of the 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Nasopharyngeal Carcinoma by Ming-Yuan Chen, or all of them as a file.
02

Study summary

In order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial. The aim is to evaluate the efficacy and safety of two treatment modalities - local region reduced-target radiotherapy versus full-target radiatiotherapy (with/without CTV2) for newly diagnosed distant metastasis nasopharyngeal carcinoma, based on the full-course immunotherapy and full-dose chemotherapy. The primary endpoints are 2-year PFS and the incidence of grade 3 or higher radiation-related adverse events. If non-inferiority is confirmed, a new standard of "immunotherapy combined with reduced-target radiotherapy" will be established, ensuring efficacy while significantly reducing toxicity, and providing a more optimal comprehensive treatment strategy for nasopharyngeal carcinoma.

Read the detailed description

Nasopharyngeal carcinoma is a highly prevalent malignant tumor in the southern regions of China, with approximately 4% to 10% of patients presenting with distant metastasis at the initial diagnosis. The five-year survival rate of traditional sole systemic chemotherapy is less than 10%, and there is an urgent need to explore more effective treatment strategies. Our team previously conducted a single-center study (402 cases) and a national multicenter retrospective study (794 cases) and first revealed that local regional radiotherapy combined with systemic chemotherapy resulted in a 60% reduction in mortality compared to systemic chemotherapy alone (HR = 0.40) (Chen MY, Chin J Cancer, 2013; Eur J Cancer, 2015). To verify this finding, with the support of the 5010 project of Sun Yat-sen University, our team initiated the world's first phase III prospective clinical trial for newly diagnosed distant metastatic nasopharyngeal carcinoma in 2014. This trial confirmed that after 6 courses of adequate systemic chemotherapy, the control group was followed up, while the experimental group received local regional full-target area adequate radiotherapy, covering the gross tumor volume (GTV), high-risk clinical target area 1 (CTV1), and low-risk clinical target area 2 (CTV2), with a total radical dose of 70 Gy, 60 Gy and 54 Gy for prophylactic radiotherapy, extending the median progression-free survival (mPFS) from 6.7 months to 12.4 months, and the 2-year PFS rate from 3.6% to 35.0%. This "adequate chemotherapy + full-target adequate radiotherapy" dual-model achieved the "Global ASCO 17 Major Clinical Oncology Breakthrough" by the American Society of Clinical Oncology in 2021, directly promoting the inclusion of local radiotherapy in the standard recommended treatment for metastatic nasopharyngeal carcinoma in the US NCCN treatment guidelines, European ESMO guidelines, Chinese CSCO guidelines and CACA guidelines (Chen MY, JAMA Oncology, 2020).

With the widespread application of PD-1 monoclonal antibodies, GP chemotherapy combined with immunotherapy (with a maximum mPFS of 21.4 months and 2-year PFS of 44.8%) has become the first-line chemotherapy regimen for recurrent/metastatic nasopharyngeal carcinoma. However, these single-drug studies did not combine local-region radiotherapy, and its value in newly diagnosed distant metastatic nasopharyngeal carcinoma has not been optimized. Therefore, our team further conducted a phase II clinical trial, sequentially administering local-region full-target radiotherapy and PD-1 monoclonal antibody during and after systemic adequate chemotherapy, and the results showed that the mPFS exceeded 30.6 months, and the 2-year PFS rate reached 54%, confirming the outstanding efficacy of the "adequate chemotherapy + half-course immunotherapy + full-target radiotherapy" triple model (Chen MY, Cell Reports Medicine, 2023).

However, the preventive irradiation area CTV2 in full-target radiotherapy has a wide coverage and is irradiated with a dose of 54 Gy or more, resulting in a 33.9% incidence of grade 3 acute mucositis and 5.2% of late hearing damage and other adverse events, severely restricting treatment tolerance. Moreover, basic research has revealed that lymph node integrity is crucial for immunotherapy, and excessive destruction of draining lymph nodes (>30 Gy) will deplete the Tim-3-TCF-1⁺ CD8+ T cell subset (with stem cell characteristics, driving long-term responses to PD-1 monoclonal antibodies), while weakening the ability of antigen-presenting cells to activate T cells, leading to impaired systemic anti-tumor immunity. Clinical retrospective analysis also indicates that patients undergoing extensive preventive lymph node dissection who received PD-1 monoclonal antibody treatment had significantly shorter PFS (HR = 0.46). Based on this, we propose the following hypothesis: In the era of immunotherapy, omitting the traditional CTV2 for the irradiation area, and exempting the low-risk invasion area of the primary lesion and the lymphatic drainage areas such as the neck II-IV zone from the preventive irradiation, can not only reduce toxicity but also preserve the lymph node immune microenvironment, thereby potentially enhancing the systemic anti-tumor response and being more conducive to the control of systemic metastatic lesions. Therefore, our team has further carried out a phase II clinical trial. After 6 courses of full-dose chemotherapy and immunotherapy, sequential local-region reduced-CTV2 radiotherapy and concurrent and maintenance immunotherapy of PD-1 monoclonal antibody were administered. The results showed that the 1-year PFS rate was as high as 77%, preliminarily suggesting that the "full-dose chemotherapy + full-course immunotherapy + reduced target radiotherapy" new triad model may be superior to the conventional full-target radiotherapy original triad model.

To further verify the effectiveness of this new model, our team intends to conduct the world's first phase III non-inferiority clinical trial for the initial treatment of advanced nasopharyngeal carcinoma. Patients with newly diagnosis distant metastatic nasopharyngeal carcinoma who respond sensitively to chemoradiotherapy will be included. Under the full-course PD-1 treatment, they will randomly receive reduced-target radiotherapy (GTV + CTV1) or full-target radiotherapy (GTV + CTV1 + CTV2). The primary endpoints are the 2-year PFS rate (non-inferiority threshold HR = 1.5) and the incidence of grade 3 or higher radiotherapy-related adverse events.

The innovation of this research lies in: pioneering a new radiotherapy strategy under nasopharyngeal carcinoma immunotherapy that exempts the preventive irradiation of low-risk areas; revealing the mechanism correlation between reduced-target radiotherapy and the dynamics of immune cell subgroups; providing evidence-based evidence for "minimal irradiation" in immunotherapy for solid tumors.

If the study confirms non-inferiority, it will achieve three major translational values: clinical level, establishing a new standard of "reduced-target radiotherapy - immune synergy"; scientific level, clarifying the regulatory role of lymph node microenvironment in radiotherapy and immunotherapy; social level, optimizing the allocation of medical resources by improving the quality of life of patients and their treatment compliance. The implementation of this study will challenge the traditional full-target radiotherapy paradigm, providing a more efficient and less toxic reduced-target radiotherapy scheme for metastasis nasopharyngeal carcinoma, as well as locally advanced nasopharyngeal carcinoma and even other solid tumors, with significant clinical and scientific significance.

03

Conditions studied

  • Nasopharyngeal Carcinoma (NPC)

Keywords

  • Distant Metastasis Nasopharyngeal Carcinoma
  • Full Course Immunotherapy
  • Reduced-Target Radiotherapy
  • Full-dose Chemotherapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years - 70 years.
  • The patient has signed the form and is willing and able to follow the visit schedule, treatment plan, laboratory tests and other research procedures as per the research plan.
  • Newly diagnosed distant patients who achieved complete response (CR) or partial response (PR) after receiving adequate systematic therapy (platinum-containing doublet chemotherapy + monoclonal antibody).
  • Nasopharyngeal carcinoma non-keratinizing carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III), confirmed by histological and/or cytological examination, with metastatic lesions detected on imaging ( of metastatic tissue is preferred but not mandatory).
  • Clinical stage: TanyNanyM1, stage IVB (AJCC 9th edition).
  • score: 0-1.
  • Female subjects with reproductive capacity must have a negative urine or serum pregnancy test within 7 days prior to enrollment, and must agree to take effective measures during the study.
  • For male subjects, if the female partner still has reproductive capacity, the male subject must agree to take effective contraceptive measures during the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with malignant pleural effusion or those with other malignant tumors
  • Patients who have received ≥2 .
  • Patients with known or suspected diseases, including dementia and epileptic seizures.
  • Patients with grade ≥ II coronary heart disease, arrhythmia (including prolongation in males > 450 ms, females > 470 ms) and heart failure.
  • Patients who received systemic or local treatment within 4 weeks prior to enrollment.
  • Patients with comorbidities requiring long-term use of drugs or requiring systemic or local use of corticosteroids at immunosuppressive doses.
  • Patients with active pulmonary tuberculosis (TB), who are undergoing anti-TB treatment or have received anti-TB treatment within 1 year prior to screening.
  • -positive individuals; positive and HBV DNA copy number positive (quantitative detection ≥ 1000 cps/ml); chronic blood screening positive (HCV antibody positive).
  • Patients who received any anti-infective vaccine (such as influenza vaccine, varicella vaccine, etc.) within 4 weeks prior to enrollment.
  • At the time of randomization, the expected lifespan of the patients was less than 6 months.
  • Other patients deemed unsuitable for inclusion by the treating physicians.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Reduced-Target Radiotherapy after Full-dose Chemotherapy under Full-course Immunotherapy

    Immunotherapy: Patients received maintenance treatment with PD-1 monoclonal antibody (a 3-week course as one cycle) until disease progression or reach 2 years. Chemotherapy: Platinum-containing doublet chemotherapy (before enrollment, 4-6 cycles) and concurrent cisplatin during radiotherapy. Radiotherapy: Patients received intensity-modulated radiotherapy technology. Experimental group: GTVnx: 69.96 Gy/33 Fr/2.12 Gy; GTVnd: 69.96 Gy/33 Fr/2.12 Gy; CTV1: 60.60 Gy/33 Fr/1.82 Gy; GTV2: No prescription dose (only delineated, actual dose is scattered dose).

    Radiation: Reduced-Target Radiotherapy

  • Active comparator
    Conventional Full-Target Radiotherapy after Full-dose Chemotherapy under Full-course Immunotherapy

    Immunotherapy: Patients received maintenance treatment with PD-1 monoclonal antibody (a 3-week course as one cycle) until disease progression or reach 2 years. Chemotherapy: Platinum-containing doublet chemotherapy (before enrollment, 4-6 cycles) and concurrent cisplatin during radiotherapy. Radiotherapy: Patients received intensity-modulated radiotherapy technology. Control group: GTVnx: 69.96 Gy/33 F/2.12 Gy; GTVnd: 69.96 Gy/33 F/2.12 Gy; CTV1: 59.4 Gy/33 F/1.8 Gy; CTV2: 54 Gy/33 F/1.64 Gy.

    Radiation: Conventional Full-Target Radiotherapy

Interventions

  • RadiationReduced-Target Radiotherapy

    Experimental group: GTVnx: 69.96 Gy/33 Fr/2.12 Gy; GTVnd: 69.96 Gy/33 Fr/2.12 Gy; CTV1: 60.60 Gy/33 Fr/1.82 Gy; GTV2: No prescription dose (only delineated, actual dose is scattered dose).

  • RadiationConventional Full-Target Radiotherapy

    Control group: GTVnx: 69.96 Gy/33 F/2.12 Gy; GTVnd: 69.96 Gy/33 F/2.12 Gy; CTV1: 59.4 Gy/33 F/1.8 Gy; CTV2: 54 Gy/33 F/1.64 Gy.

06

What researchers measure

Primary outcomes

  1. 2-year Progression-Free Survival (PFS)

    The PFS was defined as the duration from the date of random assignment to the date of disease progression or censored at the date of the last follow-up.

    Time frame: 2 years

  2. The incidence rate of radiotherapy-related ≥ grade 3 adverse events

    Including the evaluation of acute subjective and objective toxic reactions as well as the evaluation of late subjective toxic reactions. The NCI-CTC 5.0 standard and RTOG standard were adopted.

    Time frame: 2 years

Secondary outcomes

  1. Objective Response Rate(ORR)

    Defined as the proportion of patients who, after receiving treatment, have achieved complete response (CR) or partial response (PR) and maintain this state for a certain period of time (evaluated by the investigator according to RECIST 1.1)

    Time frame: 2 years

  2. Disease control rate (DCR)

    Defined as the proportion of patients who achieve CR + PR + SD after receiving treatment, and maintain this state for at least 4 weeks.

    Time frame: 2 years

  3. Overall survival time (OS)

    Defined as the time interval from the start of randomization, due to any cause, death occurs (if no death, censored at the last known survival date).

    Time frame: 2 years

  4. Health-related Quality of Life

    Changes from baseline in patient-reported quality of life scores assessed every 2 cycles using the EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, version C30). The scores range from 0 to 100, with higher scores indicating a better quality of life outcome.

    Time frame: 2 years

  5. Adverse Events Reporting

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 2 years

  6. Head and Neck Cancer-Specific Quality of Life

    Changes from baseline in head and neck cancer-specific symptoms and functions assessed every 2 cycles using the EORTC QLQ-H\&N35 module (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Head and Neck Cancer Module). The scores range from 0 to 100, with higher scores indicating a better quality of life outcome and lower scores indicating worse symptoms or functions.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000 Recruiting
    Zhuhai, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2030, 63 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 63 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2025
First posted
Sep 23, 2025
StartActual
Aug 20, 2025
Primary completionEst.
Dec 1, 2030
CompletionEst.
Jul 1, 2031
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07188584
Lead sponsor
Ming-Yuan Chen
Collaborators
Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guangxi Medical University, Fujian Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University, Sun Yat-Sen University Cancer Center, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital, West China Hospital, Xiangya Hospital of Central South University, Affiliated Cancer Hospital of Shantou University Medical College, Yunnan Cancer Hospital, First Affiliated Hospital of Kunming Medical University, Wuzhou Red Cross Hospital, Zhongshan People's Hospital, Guangdong, China, Southern Medical University, China
Responsible party
Ming-Yuan Chen (Professior, Sun Yat-sen University) — Sponsor-investigator
First posted
Sep 23, 2025
Start date
Aug 20, 2025
Primary completion
Dec 1, 2030 (estimated)
Completion
Jul 1, 2031 (estimated)
Last update
Dec 9, 2025

Study contacts

Ming-Yuan Chen, MD,PhD
Contact
chmingy@mail.sysu.edu.cn
86-13903052650
Rui You, MD, PhD
Contact
your5@mail.sysu.edu.cn
13580439820

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion